Paper40533769
Aurora kinases signaling in cancer: from molecular perception to targeted therapies.
Vats P and 6 others. Mol Cancer, 2025. Cited by 29 papers, by iCite.
Cite this record
ConductScience Library. Aurora kinases signaling in cancer: from molecular perception to targeted therapies. Papers, record 40533769. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40533769
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Neoplasms | Major topic |
| Aurora Kinases | Major topic |
| Molecular Targeted Therapy | Major topic |
| Protein Kinase Inhibitors | Major topic |
| Signal Transduction | Major topic |
| Humans | |
| Animals | |
| Antineoplastic Agents |
Source PubMed
References360
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 19567821 | GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models. | Mol Cancer Ther | 2009 | https://conductscience.org/library/papers/19567821 | PubMed |
| 2 | 31837959 | Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial. | Lancet Haematol | 2020 | https://conductscience.org/library/papers/31837959 | PubMed |
| 3 | 20560971 | Preclinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD-2076, against multiple myeloma. | Br J Haematol | 2010 | https://conductscience.org/library/papers/20560971 | PubMed |
| 4 | 39589337 | Phase I/II Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell Carcinomas. | Clin Cancer Res | 2025 | https://conductscience.org/library/papers/39589337 | PubMed |
| 5 | 8293973 | Isolation and characterization of chromosome-gain and increase-in-ploidy mutants in yeast. | Genetics | 1993 | https://conductscience.org/library/papers/8293973 | PubMed |
| 6 | 29551775 | Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial. | Br J Cancer | 2018 | https://conductscience.org/library/papers/29551775 | PubMed |
| 7 | 20001553 | Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics. | Expert Opin Investig Drugs | 2010 | https://conductscience.org/library/papers/20001553 | PubMed |
| 8 | 15501446 | Aurora kinases in spindle assembly and chromosome segregation. | Exp Cell Res | 2004 | https://conductscience.org/library/papers/15501446 | PubMed |
| 9 | 34465813 | Genetic variations in AURORA cell cycle kinases are associated with glioblastoma multiforme. | Sci Rep | 2021 | https://conductscience.org/library/papers/34465813 | PubMed |
| 10 | 34083040 | Mitotic syndicates Aurora Kinase B (AURKB) and mitotic arrest deficient 2 like 2 (MAD2L2) in cohorts of DNA damage response (DDR) and tumorigenesis. | Mutat Res Rev Mutat Res | 2021 | https://conductscience.org/library/papers/34083040 | PubMed |
| 11 | 36509911 | Rational combinations of targeted cancer therapies: background, advances and challenges. | Nat Rev Drug Discov | 2023 | https://conductscience.org/library/papers/36509911 | PubMed |
| 12 | 35868306 | Integrative analysis of drug response and clinical outcome in acute myeloid leukemia. | Cancer Cell | 2022 | https://conductscience.org/library/papers/35868306 | PubMed |
| 13 | 21206969 | Quercetin inhibits a large panel of kinases implicated in cancer cell biology. | Int J Oncol | 2011 | https://conductscience.org/library/papers/21206969 | PubMed |
| 14 | 34866972 | Hesperidin and its aglycone hesperetin in breast cancer therapy: A review of recent developments and future prospects. | Saudi J Biol Sci | 2021 | https://conductscience.org/library/papers/34866972 | PubMed |
| 15 | 19155085 | The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma. | J Hepatol | 2009 | https://conductscience.org/library/papers/19155085 | PubMed |
| 16 | 25882311 | Daurinol Enhances the Efficacy of Radiotherapy in Lung Cancer via Suppression of Aurora Kinase A/B Expression. | Mol Cancer Ther | 2015 | https://conductscience.org/library/papers/25882311 | PubMed |
| 17 | 38001709 | Expression of Soluble Form of Aurora A as a Predictive Factor for Neoadjuvant Therapy in Breast Cancer Patients: A Single-Center Pilot Study. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/38001709 | PubMed |
| 18 | 37958352 | Role of Non-Coding RNAs in Hepatocellular Carcinoma Progression: From Classic to Novel Clinicopathogenetic Implications. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/37958352 | PubMed |
| 19 | 34967265 | Co-treatment with miR-21-5p inhibitor and Aurora kinase inhibitor reversine suppresses breast cancer progression by targeting sprouty RTK signaling antagonist 2. | Bioengineered | 2022 | https://conductscience.org/library/papers/34967265 | PubMed |
| 20 | 21785464 | Dual inhibition of SRC and Aurora kinases induces postmitotic attachment defects and cell death. | Oncogene | 2012 | https://conductscience.org/library/papers/21785464 | PubMed |
Cited by28
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 29 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42821234 | ASO Author Reflections: Clinical Relevance of Aurora Kinase A (AURKA) Gene Expression in ER+/HER2- Breast Cancer. | Ann Surg Oncol | 2026 | https://conductscience.org/library/papers/42821234 | PubMed |
| 42794728 | Expanding Synthetic Lethality in DNA Damage Response-Defective Cancers Through Stress Phenotype-Guided Kinase Targeting. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42794728 | PubMed |
| 42789740 | Aurora kinase a phosphorylates and stabilizes UHRF1 to maintain DNA methylation and prostate cancer cell survival. | Epigenetics | 2026 | https://conductscience.org/library/papers/42789740 | PubMed |
| 42773299 | Pharmacological inhibition of UBASH3B induces mitotic arrest and selectively reduces tumor growth. | EMBO Mol Med | 2026 | https://conductscience.org/library/papers/42773299 | PubMed |
| 42760281 | Chromosomal instability in cancer: sources, consequences and new therapeutic opportunities. | Signal Transduct Target Ther | 2026 | https://conductscience.org/library/papers/42760281 | PubMed |
| 42749405 | Investigating the prognostics and theranostic cell cycle-related genes of Hinokinin in high-grade glioma: an integrated network pharmacology, bioinformatics, and molecular docking approach. | J Genet Eng Biotechnol | 2026 | https://conductscience.org/library/papers/42749405 | PubMed |
| 42706431 | Aurora A exacerbates antibiotic-resistant Staphylococcus aureus infection through ASC phosphorylation. | EMBO Rep | 2026 | https://conductscience.org/library/papers/42706431 | PubMed |
| 42671316 | Cancer cell-selective ectopic expression of CD20 as an antigen enables rituximab repurposing for solid tumour immunotherapy. | Clin Transl Med | 2026 | https://conductscience.org/library/papers/42671316 | PubMed |
| 42645201 | A Regulatory Element in the Intrinsically Disordered C-Terminal Region of LMTK3 Modulates Its Kinase Domain Interactions and Breast Cancer Phenotypes. | Cells | 2026 | https://conductscience.org/library/papers/42645201 | PubMed |
| 42640371 | Exceptional treatment responses and molecular markers among 103 colorectal cancer cell lines. | Mol Biomed | 2026 | https://conductscience.org/library/papers/42640371 | PubMed |
| 42578512 | Structure-based screening and identification of a novel Aurora-A-targeting peptide with antiproliferative activity against prostate cancer cells. | J Enzyme Inhib Med Chem | 2026 | https://conductscience.org/library/papers/42578512 | PubMed |
| 42531323 | Combination AURKA and WEE1 Inhibition Exhibits Efficacy in EGFR or Pan-ERBB Inhibitor-Resistant Head and Neck Squamous Cell Carcinoma. | Cancer Res Commun | 2026 | https://conductscience.org/library/papers/42531323 | PubMed |
| 42490878 | Aurora kinase B as a therapeutic target in HPV-induced cervical cancer: mechanisms and future perspectives. | Front Oncol | 2026 | https://conductscience.org/library/papers/42490878 | PubMed |
| 42445377 | LINC01614 favors breast cancer progression through the regulation of miR-217/FN1 and mediation in PI3K/AKT signal pathway. | Transl Cancer Res | 2026 | https://conductscience.org/library/papers/42445377 | PubMed |
| 42380670 | AURORA A interacts with DICER and SETD2 to promote S-phase progression. | EMBO Rep | 2026 | https://conductscience.org/library/papers/42380670 | PubMed |
| 42307783 | Multi-omics analysis positions DNA2 at the interface of genome integrity programs and tumor behavior in pan-cancer. | Funct Integr Genomics | 2026 | https://conductscience.org/library/papers/42307783 | PubMed |
| 42199350 | TPX2 as a prognostic biomarker and potential therapeutic target for malignant melanoma proliferation and metastasis. | Exp Ther Med | 2026 | https://conductscience.org/library/papers/42199350 | PubMed |
| 42092929 | Interferon lambda in anti-viral defense and cancer: dual roles, mechanism and therapeutic potential. | J Transl Med | 2026 | https://conductscience.org/library/papers/42092929 | PubMed |
| 42042038 | Dysregulation of Aurora Kinases and AURKAIP1 Promoter Methylation as Potential Peripheral Diagnostic Biomarkers in Acute Myeloid Leukemia. | Curr Issues Mol Biol | 2026 | https://conductscience.org/library/papers/42042038 | PubMed |
| 42028206 | Discovery of thieno[2,3-d]pyrimidine-based dual Aurora B/VEGFR-2 inhibitors with potent anticancer activity: molecular docking, mechanistic studies, and in vivo validation in a breast cancer model. | RSC Adv | 2026 | https://conductscience.org/library/papers/42028206 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| AURKA | 6790 | PubTator's text mining | https://conductscience.org/library/genes/6790 | NCBI Gene |
| AURKB | 9212 | PubTator's text mining | https://conductscience.org/library/genes/9212 | NCBI Gene |
| AURKC | 6795 | PubTator's text mining | https://conductscience.org/library/genes/6795 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40533769
GET https://conductscience.org/api/papers/v1/40533769/references?page=2